Skip to main content
Premium Trial:

Request an Annual Quote

Microsoft Tapped to Provide Cloud Compute, Support for TeraDiscoveries Drug Research


TeraDiscoveries and Microsoft this week announced a partnership under which Microsoft will provide support and cloud computing time on its Windows Azure platform, which TeraDiscoveries will use to identify inhibitors of 25 biological targets.

Specifically, TeraDiscoveries will use its Inverse Design computational modeling software running on the Azure platform to mine virtual chemical libraries to find the strongest inhibitors of specific biological targets that have good clinical trial properties and have a low probability of toxic side effects, the company said.

Ed Addison, TeraDiscoveries CEO, said in statement that the partnership with Microsoft provides a more efficient and cost-effective approach for searching the chemical space than traditional methods offer.

He added that the arrangement will enable the company to forge partnerships with smaller pharmaceutical or medical research companies who are interested in further developing these molecules.

These companies can purchase licenses to Inverse Design and run it on Azure as part of their efforts to design, discover, or optimize new small molecule or peptide drugs for their targets, TeraDiscoveries said. The company also offers drug discovery services.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.